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Abstract 
Background: The structure of HIV-1 envelope glycoprotein (Env) is flexible and heterogeneous on whole virions. 
Although functional Env complexes are thought to require trimerization of cleaved gp41/gp120 heterodimers, vari-
able processing can result in the potential incorporation of non-functional uncleaved proteins (gp160), non-trimeric 
arrangements of gp41/gp120 heterodimers, and gp120 depleted gp41 stumps. The potential distribution of func-
tional and non-functional Env forms across replication-competent viral populations may have important implications 
for neutralizing and non-neutralizing antibody functions. This study applied an immuno-bead viral capture assay 
(VCA) to interrogate the potential distribution (heterologous vs homologous) of functional and non-functional forms 
of virion associated Env.
Results: The VCA revealed a significant association between depletion of infectious virions and virion Env incorpora-
tion, but not between infectivity and p24-gag. Three distinct subpopulations of virions were identified within pools 
of genetically homogenous viral particles. Critically, a significant subpopulation of infectious virions were exclusively 
captured by neutralizing antibodies (nAbs) indicative of a homologous distribution of functional trimeric Env forms. 
A second infectious subpopulation bound both neutralizing and non-neutralizing antibodies (nnAbs) representative 
of a heterologous distribution of Env forms, while a third non-infectious subpopulation was predominantly bound by 
nnAbs recognizing gp41 stumps.
Conclusions: The observation that a distinct and significant subpopulation of infectious virions is exclusively cap-
tured by neutralizing antibodies has important implications for understanding antibody binding and neutralization, as 
well as other antibody effector functions.
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Background
Successful vaccination to prevent HIV-1 acquisition will 
likely require the elicitation of neutralizing antibodies 
(nAb) directed against the functional envelope glyco-
protein (Env) [1–3]. However, although natural infection 
rapidly induces Env specific class switched B cells [4], 
these lack the required specificity to provide potent and 
broad viral neutralization. Indeed maturation of autolo-
gous nAbs requires months to years of persistent sys-
temic infection [3], where <1  % of individuals develop 
substantial breadth of heterologous neutralization (elite 
neutralizers) [5–7]. Thus the features of Env variants that 
lead to neutralization breadth remain to be defined.
The predominance of antibodies that fail to neutral-
ize HIV-1 in infected individuals is thought to be due in 
part to the diversity of Env conformations presented to 
the humoral immune system. Virion Env diversity is gen-
erated by multiple mechanisms including: the range of 
virion incorporated Env structures, the degree and extent 
of Env glycosylation, the flexible nature of the HIV-1 Env 
protein, and potential instability on the surface of viral 
particles [8–10].
HIV-1 Env is expressed in infected cells as a non-func-
tional precursor protein gp160. Subsequent proteolytic 
cleavage of gp160 by cellular furins into non-covalently 
attached transmembrane gp41 and external gp120 com-
ponents is a necessary step in the creation of functional 
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Env [11]. The non-covalent nature of the cleaved gp41/
gp120 protein provides an intrinsic instability that is dis-
tinct from heterodimeric Env proteins of other viruses 
such as influenza, which retains a stabilizing disulfide 
bond [12]. The instability of the gp41/gp120 heterodi-
mer can lead to gp120 shedding leaving gp41 stumps 
expressed on the virus or infected cells. Although func-
tional Env complexes are thought to require gp41/
gp120 trimerization, variable gp160 processing results 
in the expression of uncleaved proteins and non-trimeric 
arrangements of gp41/gp120 heterodimers on the surface 
of infected cells [13]. Assembly of these Env structures 
into budding virions provides further variability, with 
gp41/gp120 incorporated as monomeric, dimeric and 
trimeric forms [13–15]. Additional diversity is derived 
from the range of gp120 glycosylation patterns that can 
obfuscate the Env spike from humoral responses. The 
array of gp120  N-linked oligomannose glycans is inef-
ficiently trimmed by Golgi and Endoplasmic Reticulum 
α-mannosidases [16, 17], and this is further reduced by 
the steric constraints imposed by trimerization [18].
The plasticity of the Env complex itself leads to vari-
able and transient epitope exposure further confound-
ing the potential elicitation of nAb responses [19]. This is 
enhanced by the fact that a series of conformational rear-
rangements occur during receptor triggering and viral-
cell fusion [20, 21]: the co-receptor (CCR5 or CXCR4) 
binding site is exposed after binding to the CD4 mol-
ecule; and the fusion peptide of gp41, that inserts into 
the target cell and initiates membrane fusion, is only fully 
exposed following CD4 and co-receptor binding.
The inherent flexibility and high potential energy of the 
Env complex is likely necessary for correct functioning, 
but this complicates the development of effective mimic 
immunogens for use in vaccination regimes. Nonethe-
less, a growing number of broadly neutralizing monoclo-
nal antibodies (mAbs) have been isolated from a few elite 
controllers that map to sub-regions on the Env spike [22–
24]. These include PG9, PG16, VRC01 and VRC03 mAbs 
that are understood to recognize gp120 in the context 
of functional trimers, and display very broad breadth of 
neutralization in comparison to the previously identified 
CD4 binding site (CD4bs) b12 mAb and glycan specific 
2G12 mAb [25, 26]. Additional very potent broadly nAbs 
(bnAbs) targeting gp120 have recently been described 
[22, 27]. In rare instances nAbs have also been isolated 
from infected subjects that map to the gp41 membrane 
proximal external region (MPER), including 4E10, 2F5 
and 10e8 mAbs [28–31].
Although binding to functional oligomeric Env is 
thought to be essential for neutralization, the extent 
to which bnAb discriminate between functional and 
non-functional Env is not fully defined. Furthermore, 
the distribution of variant Env forms across replica-
tion competent viral populations may have profound 
implications for nAb and nnAb function [32]. It remains 
unclear whether functional and non-functional Env vari-
ants are distributed randomly or whether there is dif-
ferential partitioning forming discrete subpopulations 
of virions. Indeed, the extent to which individual virions 
are heterologous or homologous with respect to expres-
sion of functional and non-functional Env is unknown. 
This has functional significance as only a fraction of 
these structures may present epitopes that are suscep-
tible to antibody neutralization, while non-functional 
forms may be subject to binding by nnAbs and subse-
quent virion opsonization rendering virions susceptible 
to FcR effector functions including antibody-dependent 
cellular phagocytosis (ADCP) [33]. In this study, using 
an immuno-bead based viral capture assay (VCA) and a 
panel of antibodies of known specificities, we investigate 
the potential distribution (heterologous vs homologous) 
of functional and non-functional forms of virion associ-
ated Env.
Results
Env‑specific mAbs capture varying levels of total  
viral particles and gp120 positive virions
An immuno-bead VCA was used to interrogate variabil-
ity in the structure and conformation of Env glycopro-
tein incorporated into intact virions. Viral capture was 
assessed using a panel of nAb and nnAb, as well as mAbs 
to host derived proteins HLA-DR and CD45, which have 
been reported as selectively included or excluded from 
viral particles respectively. mAbs were incubated with 
highly purified viral preparations, followed by incubation 
with protein G coupled paramagnetic beads to capture 
antibody-coated virus. The antibody-bead labeled posi-
tive fraction was then separated from free virions (nega-
tive fraction) by retention on a magnetic column. Specific 
protein content (p24 or gp120) of the retained positive 
fraction was expressed as a percentage of the sum of the 
positive and negative fractions combined. Virion-asso-
ciated p24, considered as evenly distributed amongst 
virions, was used to quantify the total amount of virus 
present. The use of purified viral preparations, free from 
non-viral associated p24, enabled quantitation of virions 
in the labeled fraction as a portion of the whole. Virion-
associated gp120 was used to quantify capture of gp120 
positive virions.
Both total virion capture (p24) and capture of gp120 
positive virions varied by antibody (Table  1). There was 
no correlation between whole virion (p24) and gp120 cap-
ture (Fig.  1a) and no predictive value of relative capture 
from one parameter to the other (Spearman R = 0.3289, 
p  >  0.05, Fig.  1b). This is unsurprising given that virions 
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homologous for gp41 stumps would not be captured by 
antibodies to gp120. Indeed antibodies targeting gp41 
epitopes in MPER and cluster I (C1) were associated with 
a low gp120:p24 ratio (<1), while those targeting exposed 
epitopes on trimeric Env were generally associated with 
ratio’s >1. These data suggest differential depletion of a 
mixed population of virions expressing different Env forms 
where no individual antibody could capture all virions.
There was negligible decrease in total virion capture 
(p24) between virus harvested after 24 or 72 h of culture 
in fresh media (p = 0.068, ANOVA), indicating that the 
differences in the relative proportions of virus capture 
between antibodies (gp120:p24) were an inherent aspect 
of early viral particle production and did not arise from 
a progressive degradation of Env in culture (Fig.  2a). 
Degradation of virus was not seen to occur during time-
scales of VCA, requiring sustained incubation at elevated 
temperature to degrade infectivity (Fig.  2b). Combining 
mAbs that recognize gp120 (b12 or PG9) and gp41 (4B3 
and 2F5) together resulted in enhanced capture with the 
majority of virions being bound (Fig. 1c), confirming that 
measured p24 was exclusively derived from intact viral 
particles. The efficiency of viral particle capture was also 
confirmed for select antibodies (b12, b6, 2F5, and 4B3) 
by nanoparticle tracking analysis that allows direct physi-
cal quantification of virion particles (Fig.  3) [34]. These 
results correlated significantly with the quantification of 
total viral particles assessed by p24 content (Spearman 
R = 0.9000, p < 0.05).
Table 1 Viral capture of HIV-1 with a panel of monoclonal 
antibodies measured by p24 or gp120
Viral capture measured by particle and Env retention. Data shown are means 
and standard deviation, with n ≥ 3
ND not determined
Antibody Binding epitope % p24 % gp120 gp120:p24
b12 gp120 CD4bs 50.9 (1.0) 75.2 (1.3) 1.48
b6 gp120 CD4bs 34.2 (7.9) 23.8 (3.7) 0.70
1F7 gp120 CD4bs 34.9 (1.7) 52.0 (1.8) 1.49
VRC01 gp120 CD4bs 28.6 (4.2) 78.2 (3.8) 2.73
VRC03 gp120 CD4bs 61.0 (1.6) 85 (12.9) 1.39
17b gp120 CD4i 28.3 (7.1) 35.0 (6.7) 1.24
PG9 gp120 V2/V3 loop 69.0 (5.2) 51.4 (7.9) 0.74
PG16 gp120 V2/V3 loop 51.0 (1.2) 90.5 (14.6) 1.77
2G12 gp120 mannose 15.3 (0.6) 64.0 (3.2) 4.18
4B3 gp41 cluster I 60.1 (7.2) 22.1 (3.2) 0.37
3D6 gp41 cluster I 61.8 (2.4) 18.3 (5.3) 0.30
F240 gp41 cluster I 52.7 (8.1) ND ND
7B2 gp41 cluster I 39.6 (2.4) ND ND
5F3 gp41 cluster V 42.2 (9.4) ND ND
2F5 gp41 MPER 47.4 (1.2) 18.3 (1.3) 0.39
4E10 gp41 MPER 32.1 (2.3) 8.1 (0.5) 0.25
HLA-DR Host protein 52.7 (4.6) 42.0 (7.6) 0.80
CD45 Host protein 1.1 (0.1) 0.1 (0.1) 0.09
IgG isotype Non-specific 1.0 (0.0) 1.1 (0.1) 1.10
Fig. 1 Capture of purified virus by a panel of monoclonal antibod-
ies against Env epitopes and host-derived proteins. Purified HIV-1BaL 
virions incubated with a range of antibodies were then retained 
on magnetic protein G microbeads. The retained, positively bound 
fraction was expressed as a proportion of the total protein, quantified 
by either p24 or Env capture ELISA. a Pair-wise representation of 
the antibody binding to virions when quantified by p24 or gp120 
capture. The Wilcoxon matched pairs T Test between p24 and gp120 
was insignificant, p = 0.6495. b There was no significant correlation 
between increased % p24 capture with % gp120 capture. c Com-
bined antibodies in capture assays were quantified by p24 retention, 
and show an additive effect of combining antibodies targeting mul-
tiple Env epitopes. Capture assays were performed in triplicate, and 
repeated three times. Error bars represent the standard deviation
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Capture of virions with varying Env conformation 
and cleavage states is determined by antibody specificity
Native PAGE was used to further understand the differ-
ential depletion of mixed populations of virions by select 
antibodies. Trimeric gp41/gp120 was the most abundant 
form of Env on purified virions (Fig. 4a), with lower lev-
els of dimeric and monomeric forms as well as uncleaved 
gp160. Viral capture with b12, in concord with its prefer-
ential recognition of the CD4bs on trimeric Env, prefer-
entially depleted gp41/120 trimers from the viral stock, 
and also had the largest impact on total Env depletion 
(Fig. 4b, c). In contrast, b6 depletion, which binds with 
lower affinity to the CD4bs on trimeric Env [35], was 
inefficient at depleting trimeric gp41/120 relative to 
other forms of Env. MPER specific 2F5 was similarly 
inefficient at depleting trimeric gp41/120 relative to 
other forms of Env. Furthermore, while capture using 
gp41 (cluster I) specific 4B3 efficiently depleted gp41 
trimers devoid of gp120 (Fig.  4c), it was the least effi-
cient at depleting structures containing gp120 or gp160 
(Fig.  4b). These data are in agreement with the relative 
proportions of total gp120 detected by ELISA (Table 1).
Parallel analysis was performed by SDS-PAGE 
(Fig. 5a). Cleaved gp120 (gp120 Gly) was the predomi-
nant species detected by gp120 mAbs on untreated 
purified virions with a lower proportion of uncleaved 
gp160 forms (Fig.  5a). These data concord with native 
PAGE where the predominant form of virion-associ-
ated Env was trimeric gp41/120. Viral capture with 
b12 resulted in over 90  % depletion of gp120 Gly and 
gp41, confirming the preferential depletion of trim-
eric gp41/120 by native PAGE. b12 capture resulted in 
lower depletion of gp160 Gly, and only minor depletion 
of alternatively glycosylated gp160 forms. Comparison 
of fold change in gp120/gp160 species relative to gp41 
revealed an enrichment of all gp160 species following 
b12 capture (Fig. 5b). This indicates preferential deple-
tion of a distinct subpopulation of viral particles within 
the viral stock: those expressing cleaved gp41/120—
captured by b12, and those expressing uncleaved gp160 
that as a consequence of preferential gp41/120 deple-
tion were enriched relative to gp41. By contrast, b6 and 
4B3 capture displayed a modest preferential targeting of 
uncleaved gp160 resulting in a small reduction in gp160 
forms relative to gp41. 2F5 capture had no effect on the 
ratio of gp120/160:gp41 reflecting a modest reduction 
in all Env forms.
Env‑specific mAbs bind to and capture varying amounts 
of infectious HIV‑1
The VCA was then modified to assess depletion of infec-
tious HIV-1BaL virions. Here, virus was incubated with 
antibody of interest, followed by depletion with protein 
G beads. The bound fraction was retained on a column 
and the eluted virus assessed for infectivity. Depletion of 
infectious virus was determined as percentage change in 
the area under the curve relative to the IgG isotype con-
trol. In line with their specificity for functional forms of 
Env, neutralizing antibodies targeting gp120 captured 
and consequently efficiently depleted infectious particles 
(Fig.  6). In contrast antibodies preferentially targeting 
gp41 or non-trimeric forms of Env (b6) were ineffective 
(Fig. 6, Additional file 1: Figure S1).
For HIV-1BaL there was no correlation between p24 and 
infectivity capture (R = 0.2464, p > 0.05; Fig. 7a), similar 
to the lack of association between p24 and gp120 positive 
populations. However, a strong correlation was found 
between the gp120 positive population and infectivity 
depletion (Spearman R  =  0.8418, p  <  0.0001; Fig.  7b). 
These data are concordant with trimeric Env being the 
predominant form within the virion population. The abil-
ity of antibodies VRC01, 2G12 and IF7 to capture over 
90 % of infectious virions but less than 35 % of viral par-
ticles (p24) demonstrates that functional Env molecules 
are not evenly distributed amongst virions. Furthermore, 
Fig. 2 Changes in viral integrity determined after a timing of virus 
harvest or b incubation at a range of temperatures. a Viral capture, 
as described in Fig. 1 legend, with 5 antibodies was determined by 
% p24 capture when virus was harvested 24 or 72 h after final media 
change. b Viral infectivity was measured on TZM-bl cells after virus 
was stored at the indicated temperature for up to 96 h. Data shown 
is the average and standard deviation of two experiments, each 
performed in triplicate
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the inability for antibodies preferentially targeting non-
functional forms of Env to capture significant amounts 
of infectious virus, while capturing a significant propor-
tion of total virions (p24) provides further evidence for 
distinct viral subpopulations: those expressing functional 
Env and consequently infectious, and non-infectious viri-
ons expressing non-functional forms. Subsequent experi-
ments were designed to determine the extent of potential 
overlap in the distribution of these different Env forms on 
virions within the same viral population.
Because HIV-1BaL is a lab-adapted virus we next con-
sidered depletion of primary strains. Similar levels of 
infectious capture were seen for a smaller panel of nAbs 
tested against clade B primary clinical isolate Bx08 (Addi-
tional file  2: Figure  S2A). With the clade C transmitted/
founder virus CH162.c, there was a weak positive correla-
tion between retaining virus particles (p24) and infectious 
virions (Spearman R = 0.5711, p = 0.04; Additional file 2: 
Figure  S2B). Capture of virus particles (p24) and gp120 
were not significantly correlated (Spearman R  =  0.4020, 
p  =  0.06; Additional file  2: Figure  2C). A highly signifi-
cant positive correlation existed between capture of infec-
tious particles and g120 (Spearman R = 0.6544, p < 0.01; 
Additional file  2: Figure  2D). While strain specific differ-
ences exist in epitope exposure, capture of infectious par-
ticles revealed a similar pattern of depletion as HIV-1BaL 
by bnAbs PG9, PG16, PGT151 and VRC01 that depleted 
more than 80  % of infectious virions. Other mAbs were 
capable of capturing substantial amounts of viral particles 
but not preferentially binding to infectious virions or gp120 
(7B2, 4B3, 4E10, 5F3). However, mAbs with a high degree 
of p24 capture did not necessarily retain much infectious 
virus and the strongest association was between capture of 
gp120 and infectious virions. No antibody activity was pre-
sent in the depleted fraction ruling out potential neutraliza-
tion of the eluted fraction (Additional file 3: Figure S3).
Sequential sorting of virions reveals three overlapping 
states of Env on viral particles
Two sequential rounds of viral capture were used to 
determine the potential overlap of functional and non-
functional Env forms within the viral population. First 
round viral capture was used to deplete virions express-
ing accessible gp41 C1 forms of Env (4B3 capture), func-
tional trimers (b12 capture) or exposed MPER epitopes 
(2F5 capture), using a standardized viral input of 1000 ng 
p24. 4B3 bound 60 % (601 ng) of virus (p24), 2F5 bound 
47 % (474 ng), while b12 bound 51 % (509 ng) (Table 2, 
first round capture). The residual depleted populations 
were collected and subject to a second round of antibody 
capture and the bound fractions determined (Table  2). 
When the same antibody was used in first and second 
round capture minimal virus was bound confirming that 
the first round of depletion was >99 % effective.
Fig. 3 Direct visualization and quantitation of viral particles after antibody depletion. a Nanoparticle tracking analysis (Nanosight) of HIV-1BaL was 
performed after depletion by 5 monoclonal antibodies. Representative still images from movies are shown. The number of virions identified by red 
makers is indicated. Nanosight quantification of (b) total particle counts and (c) % capture of viral particles after sorting. Data shown is the average 
of at least two independent experiments
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Fig. 4 Native-PAGE determination of the Env conformations present 
after virus depletion. a Purified HIV-1BaL virions were depleted by the 
antibody specified and separated on native-PAGE gels and western 
blots were probed with a gp41 (2F5, 4B3, 3D6) or gp120 (b12, 2G12, 
b6) antibody cocktail. The abundance of Env species were quanti-
fied relative to undepleted virus for blots probed with (b) gp120 
antibodies or (c) gp41 antibodies. Blot is representative of at least 3 
independent depletion experiments and quantification is the aver-
age of 3 images
Fig. 5 SDS-PAGE determination of the relative binding to Env states 
after virus depletion. a Purified HIV-1BaL virions were depleted and 
separated on SDS-PAGE gels and western blots were probed with a 
gp41 (2F5, 4B3, 3D6) or gp120 (b12, 2G12, b6) antibody cocktail. b 
The ratio of each species identified in the gp120 probed blot relative 
to gp41 is used to determine preferential binding to Env states. Blot is 
representative of 3–5 independent experiments and quantification is 
the average of 3 images
Fig. 6 Depletion of infectious particles with a panel of Env-specific, 
or host protein directed mAbs. Infectious stock of HIV-1BaL was 
depleted with a range of antibodies. The remaining depleted virus 
was titrated on TZM-bl cells and compared to virus treated with 
isotype controls. The area under the curve relative to the IgG control 
depleted preparation is used to determine % infectivity depletion. 
Data represent the mean of three independent experiments each 
performed in triplicate
Page 7 of 15Stieh et al. Retrovirology  (2015) 12:81 
Sequential capture with b12 and 4B3 (in either order) 
bound 98 % of all virions indicating that the total MPER 
accessible fraction (2F5) was represented within these 
two populations. Taking this into account it was possible 
to calculate the relative abundance of gp41 C1, CD4bs 
and MPER single, dual and triple positive virions within 
the initial viral population. Within the initial viral popu-
lation 28.4 % of virions were CD4bs single positive (b12), 
25.2  % expressed only gp41 C1 (4B3), 20.6  % were dual 
positive for gp41 C1 and MPER (2F5), 9.2 % double posi-
tive for MPER and CD4bs, and 16.6 % triple positive for 
gp41 C1, MPER and CD4bs (Fig. 8a). Thus >50 % of viri-
ons expressing functional Env (b12+) were negative for 
non-functional forms, 17 % were dual positive for CD4bs 
and MPER, and 30.6  % were triple positive for CB4bs, 
MPER and gp41 C1.
In a second experiment, sequential rounds of viral 
capture were performed with the CD4bs antibodies 
b12 and b6, preferentially recognizing functional and 
non-functional forms of gp120 respectively (Fig. 8b). First 
round b6 capture bound 27.1 % of virions, equivalent to 
271  ng of p24-associated virus from an initial input of 
1000 ng/p24. Secondary capture with b12 bound 49.1 % 
of the unbound b6 negative fraction (358  ng/729  ng). 
b12 used in first round capture bound 52 % of the origi-
nal initial non-depleted stock. Taking this into account 
we calculated the relative abundance of b6 and b12 sin-
gle and dual positive populations within the viral popu-
lation. Overall, 16.2  % of virions expressed both b6 and 
b12 CD4bs epitopes, 10.9  % expressed only b6, 35.8  % 
expressed only b12, and 37.1 % expressed neither CD4bs 
epitopes. This is consistent with b12 and b6 binding to 
largely distinct forms of Env while both targeting the 
CD4bs, and indicates that >68  % of virions positive for 
functional Env (b12+) were negative for non-functional 
forms of gp120 (b6−), while 48 % of virions in the total 
population expressed non-functional forms (b6−/b12− 
and b6+/b12−).
Fig. 7 Correlation between a % p24 or b % gp120 capture and % infectivity capture by a panel of Env-specific mAbs are shown. Spearman correla-
tion between the amount of % p24 captured and depletion of infectivity was insignificant (Spearman R = 0.2464, p > 0.05) but highly significant 
correlation exists between % gp120 binding and % infectivity capture (Spearman R = 0.8418, p < 0.01)
Table 2 Sequential sorting of  viruses with  antibodies against  varying HIV-1 Env epitopes, measured by  p24 capture 
in ng/p24 and as a percentage of p24 input
The header row describes the input virus, either total virus for the first round capture (1000 ng/p24) or the collected unbound fraction following first round depletion 
with 4B3 (399 ng/p24), b12 (491 ng/p24) or 2F5 (526 ng/p24)
Italics indicate the values after first round capture






Input: 1000 ng Input: 399 ng Input: 491 ng Input: 526 ng
ng/p24 % input ng/p24 % input ng/p24 % input ng/p24 % input
4B3 601 60.1 0.8 0.2 457.6 93.2 373.5 71.0
2F5 474 47.4 92.2 23.1 206.2 42.0 4.2 0.8
b12 509 50.9 375.9 94.2 1.0 0.2 260.4 49.5
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Depletion of non‑infectious virions has minimal impact 
on viral neutralization
Subsequent experiments were performed to assess the 
potential ‘decoy’ effect of non-functional Env on antibody 
neutralization. The relative inhibitory potency of a panel 
of nAbs (2F5, 4E10, b12, 1F7 and 2G12) was assessed fol-
lowing depletion with 3D6 or 4B3 that primarily recog-
nize non-functional Env spikes or gp41 stumps (Fig.  9). 
Depletion with 3D6 or 4B3 had no significant impact 
on neutralization of HIV-1BaL by gp120 specific nAbs: 
2G12, b12 or 1F7, confirming lack of significant overlap 
between these populations. In contrast, the neutralizing 
potency of 4E10 was strongly affected after depletion with 
either 4B3 or 3D6 epitope expressing virions (p  <  0.01, 
ANOVA, for both 4B3 and 3D6 depletion). This pattern 
was followed for 2F5 as well, with a statistically signifi-
cant decrease in IC50 following 3D6 depletion (p < 0.01, 
ANOVA) from 12.4 to 9.6 μg ml−1 and a trend towards 
increased activity following 4B3 depletion (p  =  0.063). 
Furthermore, when comparisons were made by ANOVA, 
where the 95 % confidence interval for the change in IC50 
are calculated, following 4B3 depletion the only mAbs 
that resulted in confidence intervals excluding zero were 
2F5 and 4E10. These data suggest that removal of virions 
Fig. 8 Venn diagram of the overlapping states of Env present on viral particles. Sequential viral sorting of purified HIV-1BaL virions as described in 
Fig. 1 legend, with either a 4B3, 2F5 and b12 or b b12 and b6 was quantified by p24 ELISA. The overlap between populations was determined by 
the change in % and total amount of p24 captured after a first round of depletion relative to the p24 capture of purified viral preparations. Data 
shown is the average of three experiments, performed in triplicate
Fig. 9 Effect on neutralization microvesicles was performesensitivity following depletion of non-infectious virions by 4B3 and 3D6. The IC50 of a 
panel of neutralizing antibodies against HIV-1BaL was measured against mock depleted viral stocks and the same virus after having been depleted 
by 4B3 or 3D6. The depleted virus was tested by serial dilution of antibody on TZM-bl cells. Data shown is the average of three experiments, per-
formed in triplicate. Error bars indicate standard deviation
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expressing gp41 C1 epitopes can modestly enhance the 
neutralizing potency of MPER antibodies, confirming the 
significant overlap in expression of these two epitopes 
within the viral population, but had an insignificant 
impact on nAbs targeting gp120.
Discussion
This study interrogates the distribution (heterologous vs 
homologous) of functional and non-functional forms of 
virion associated Env across viral particles. The use of an 
immuno-bead VCA enables quantitation of both bound 
and unbound fractions, which in turn allows quantitation 
of relative epitope exposure on intact virions. Although 
in-solution viral binding assays have been reported 
before [35, 36], this approach varies from previous plate 
based VCA in that all components of the system are in 
the native orientation that would be present during an 
in  vivo binding event. By using depletion rather than 
a positive selection process, we are able to characterize 
subpopulations across replication-competent viral popu-
lations. Furthermore, the use of purified virions allows 
determination of virion associated gp120 and p24 pro-
tein in the antibody associated and unbound fractions 
after capture without confounding effects of free p24 or 
gp120. Multiple low-affinity, slow and/or transient bind-
ing events are minimized by incubation times sufficient 
for viral-antibody interactions to reach equilibrium 
(98 % within 1600 s for antibodies of a similar affinity at 
10 μg ml−1, as calculated according to Hulme et al. [37]) 
in the liquid phase before capture by protein G magnetic 
beads.
The capture of p24 in this model did not correlate with 
the capture of infectious virions in agreement with pre-
vious observations [15], and confirms that a significant 
population of virions do not express functional Env [13, 
38]. Indeed the ability of antibodies VRC01, 2G12 and 
IF7 to capture over 90  % of infectious virions but less 
than 35 % of viral particles (p24) demonstrates that func-
tional Env molecules are not evenly distributed amongst 
virions (Table  1). Furthermore, no single antibody cap-
tured all virus, as assessed by p24 content or nanopar-
ticle tracking analysis, suggesting no single epitope was 
expressed (or accessible) across all virion forms within 
the population. Interestingly, antibody to HLA-DR cap-
tured 52 % of virions suggesting that HLA incorporation 
is not as uniform or ubiquitous across all viral parti-
cles as perhaps previously thought [39, 40] (Table 1). In 
contrast there was a positive and highly significant cor-
relation between gp120 and infectivity. nAbs targeting 
gp120 epitopes were highly efficient at capture of both 
infectious virus and gp120 containing virions. However, 
mAbs thought to require receptor triggered conforma-
tional change to expose their cognate epitopes on gp120 
(17b) or gp41 (2F5 and 4E10) [20, 35, 41, 42] were rela-
tively inefficient at capture of infectious virus and gp120 
positive virions alike. This reflects early observations that 
2F5 binds slowly to functional Env (several hours) and 
induces conformational change that ultimately leads to 
shedding of gp120 [43]. Furthermore, nnAbs 4B3, 3D6, 
7B2 and F240 targeting gp41 C1 or non-trimeric forms of 
gp120 (b6) captured only a minority of infectious virus, 
indicative of the occlusion or absence of their cognate 
epitope on infectious virions and lack of co-expression 
with functional forms of Env.
The high correlation between capture of gp120 con-
taining virions and capture of infectious virus by nAbs 
to gp120 may provide a correlate of the nature of infec-
tious virions whereby the majority of gp120s are attached 
to functional particles. Therefore, although processing 
of Env can give rise to monomeric, dimeric and trim-
eric forms there appears to be limited incorporation into 
infectious virus. This was confirmed by native and SDS 
PAGE that indicate the predominant form of virion asso-
ciated Env was trimeric gp120/gp41, concordant with 
previous studies [35]. These observations are dependent 
on the known specificity of individual mAbs and their 
ability to discriminate between functional and non-
functional Env forms. We cannot exclude that particles 
predominantly expressing functional Env forms may still 
express non-functional forms at a level below our sensi-
tivity of detection or at a frequency too low to facilitate 
effective viral capture.
Sequential viral sorting was applied to further interpret 
the distribution of Env structures within a purified HIV-1 
population using mAbs targeting key structures (Table 2): 
b12 binding gp120; 2F5 specific for MPER; and 4B3 spe-
cific for gp41 C1. Pair-wise sorting experiments using 
these antibodies revealed three distinct but overlapping 
subpopulations (Fig. 8a). These data suggest discrete par-
titioning of Env forms across the viral population: virions 
homologous for functional Env, those heterologous for 
functional and non-functional Env and those homolo-
gous for non-functional forms. It is unclear whether the 
different forms represent differences in viral assembly/
maturation, transitional states of Env degradation, or 
aspects of both. Previous studies indicated that released 
virus has equivalent molar amounts of integrated gp41 
and gp120 that are relatively stable [44], however the half-
life of infectious virions at 37 °C is estimated to be in the 
order of 6–18 h [45]. Virus used in most of these studies 
was harvested 72 h after media change; nevertheless, the 
timing of virus harvest (24 vs 72 h) did not significantly 
affect the proportions of virus captured. It is interesting 
to note that virus devoid of gp120 can be dual positive for 
MPER and gp41 C1 or single positive for gp41 C1. 2F5 is 
thought to preferentially bind gp41 monomers [20], while 
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4B3 is likely similar to other C1 gp41 antibodies that bind 
all multimerizations of gp41. Therefore 2F5/4B3 positive 
stumps likely encompass gp41 monomers as well as mul-
timeric forms, while 4B3 single positive stumps reflect 
only multimeric forms.
The close Gag-Env association during particle release 
is thought to constrain Env subunits into a more widely 
distributed conformation where gp41 epitopes are more 
exposed; while these epitopes become masked during 
particle maturation [46, 47] and/or cleavage of gp160 [41, 
42]. Thus virions triple positive for gp120 (b12), MPER 
(2F5) and gp41 C1 (4B3) (16.6 %) may represent a frac-
tion of immature particles and/or those with uncleaved 
gp160 within the total population, which all mAbs were 
able to deplete. Alternatively this triple positive popula-
tion may represent an intermediate state of envelope 
subunit dissociation before total loss of gp120 [13, 45]. 
Future experiments are needed to distinguish the relative 
contributions of these two options to this heterologous 
subpopulation.
To further interpret the distribution of gp120 struc-
tures within a homogenous viral population sequential 
sorting was performed using mAbs targeting functional 
(b12) and non-functional gp120 forms (b6); b6 mAb is 
thought to preferentially recognize non-trimeric gp120 
or immature trimers. Given that b6 single positive virus 
would be non-infectious, reflecting virus displaying only 
non-functional Env, then of the total infectious b12 posi-
tive virions, 64  % would be single positive for b12 and 
36 % dual positive (b6+ b12+). These data are very simi-
lar to our observation that b6 captures 32 % of infectious 
virus while b12 captures >87  % (Fig.  6). This provides a 
possible explanation as to why b6 fails to block b12 neu-
tralization despite targeting broadly overlapping epitopes 
in the CD4bs of gp120 [15].
Our data concord with previous reports that defective 
Env structures are thought to make up a large propor-
tion of the total virions [13, 48]. Removal of the non-
infectious virions that express the 4B3 or 3D6 epitopes 
depleted only a small fraction of virions susceptible to 
neutralization by 2G12, b12, or 1F7. This confirms that 
virions expressing gp120 epitopes vulnerable to neu-
tralization are largely distinct from non-infectious virus 
expressing accessible gp41 C1, most likely representing 
Env ‘stumps’which consist only of gp41 without any asso-
ciated gp120 [13]. These data complement the observa-
tions that 4B3 bound <8 % infectious virions. The impact 
of 4B3 and 3D6 depletion on the neutralization activity 
of 4E10 and 2F5 likely reflects the non-infectious popu-
lation that expresses both gp41 C1 and MPER epitopes 
(Fig.  8) acting as a potential sink for MPER targeting 
antibodies and reducing the fraction free to neutralize 
by binding Env fusogenic intermediates following CD4 
interaction on target cells. However the relatively limited 
impact on activity suggests this is unlikely to play a sub-
stantial role in vivo.
Viral capture of infectious, functional virions by nAbs 
concords with the accessibility of these sites revealed by 
recent structural data on soluble stabilized Env trimers 
[49–51]. Although some differences are expected due to 
variation in clade or effect of stabilizing mutations pre-
sent in native-like soluble trimers, we find only minor 
variations, particularly in relation to b12 capture [52]. 
However these are in accord with the recently described 
and more closely matched stabilized B41 soluble clade B 
trimer [53]. The previously described occlusion of non-
neutralizing epitopes on virion expressed functional 
trimers [48, 54] is consistent with the inefficient capture 
of infectious virions by nnAbs observed in this study. 
Recent observations that vaccination with virus-like 
particles, depleted of non-functional Env by enzymatic 
digestion, can elicit Tier 2 neutralizing responses confirm 
the importance of nAb recognition of native functional 
Env [55].
Our observation that a significant fraction of infectious 
virions were exclusively captured by nAbs is indicative 
of a homologous distribution of functional trimeric Env 
forms. Indeed, heterologous distribution of functional 
and non-functional forms represented a minor fraction 
of the total viral population, the majority of virions being 
homologous either for functional or non-functional 
forms of Env. This may have important implications for 
the design of effective antibody based prophylactic vac-
cines targeting cell free virions. The observation that a 
significant proportion of virus displaying functional Env 
was negative for binding of nnAbs brings into question 
potential mechanisms of direct functional interaction of 
such antibodies with free infectious virions. Proposed 
mechanisms of inhibition by nnAbs include: antibody 
dependent viral capture; aggregation; mucus retardation; 
transcytosis inhibition; complement mediated cytoly-
sis; and cell mediated phagocytosis (ADCP) [56]. All are 
predicated on their binding to infectious virions. While 
the smaller population of infectious virions heterolo-
gous with respect to functional and non-functional forms 
of Env would be susceptible to these mechanisms, the 
majority of virions homologous for functional Env would 
be unimpeded by such response.
Should this be the case in vivo then protective vaccines 
targeted against cell free virions may critically depend on 
recognition of functional trimers. This does not however 
exclude a potential contributing role for nnAb in elimi-
nation of infected target cells through ADCC or ADCP. 
Indeed most protective nnAbs described to date react 
with viral epitopes expressed on the surface of infected 
cells rather than the surface of virions [57].
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Conclusions
In summary, the key finding of this work is the recog-
nition that the majority of infectious virions within a 
viral population are homologous with respect to expres-
sion of functional Env, with a smaller population heter-
ologous for functional and non-functional forms. These 
observations argue against a random distribution of 
non-functional forms of Env across an infectious viral 
population. The predominant homologous distribution of 
functional Env predicates that recognition of functional 
Env is essential for antibody binding to the majority of 
infectious virions, a trait thought to be synonymous with 
neutralization. These observations should be taken into 
account in the design and selection of prophylactic vac-
cines targeting infectious virions.
Methods
Cells and reagents
TZM-bl and PM-1 cells were obtained from the NIH-
AIDS Research and Reference Reagent Program. Anti-
bodies 2F5, 2G12, 4E10, PG9, PG16, and 17b were 
obtained through the Center for HIV and AIDS Vaccine 
and Immunology (CHAVI). Antibodies 5F3, 4B3, 3D6, 
and 1F7 were obtained from Polymun Scientific, GmbH 
(Austria). Antibodies b12, b6, VRC01, and VRC03 were 
obtained from Dennis Burton, Scripps Research Insti-
tute (La Jolla, United States). The following reagents were 
obtained through the NIH AIDS Research and Reference 
Reagent Program, Division of AIDS, NIAID, NIH: Solu-
ble Human CD4 from Progenics, TZM-bl from Dr. John 
C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. T cell line 
PM-1 was donated by Dr. Marvin Reitz. HIV-1BaL was 
donated by Dr. Suzanne Gartner, Dr. Mikulas Popovic 
and Dr. Robert Gallo. Non-specific human IgG antibody 
was obtained from Sigma. Monoclonal antibodies against 
human CD45 and HLA-DR were obtained from Santa 
Cruz Biotechnology.
Viral culture and purification
HIV-1BaL and HIV-1Bx08 viral stocks were produced in 
PM-1 T-cells to reduce potential influence of donor vari-
ability when using PBMC grown virus. Briefly, 2 ×  106 
PM-1 cells were re-suspended in 1 ml of fresh medium 
(RPMI + 10 % FCS + 2 mM l-glutamine + 100 U ml−1 
Penicillin  +  100  μg  ml−1 Streptomycin) and 1  ml of 
infectious HIV-1BaL stock was added. After 3  days 
2 × 107 fresh, uninfected PM-1 cells were added to the 
culture in 20 ml of fresh medium. After 7 days, 1 × 108 
additional PM-1 cells were added to the culture and the 
total volume made up to 150 ml with fresh medium. The 
culture was further expanded on day 10 by the addition 
of 150  ml of fresh medium, taking the total volume to 
300 ml, and was harvested on day 13 by centrifugation at 
2500 rpm for 15 min. Virus was inactivated with a final 
concentration of 1  mM aldrithiol (AT-2, Sigma, UK) 
for 2.5  h at 37  °C and frozen at −80  °C. Virus concen-
tration of this stock was greater than 767  ng  ml−1 p24 
measured by HIV-1 p24-gag ELISA (Frederick) accord-
ing to the manufacturer’s instructions, and TCID50 ml−1 
on PM-1 cells was 5.2 × 106. Stocks of the transmitted/
founder (T/F) clade C virus CH162 (accession number 
KC156126, kindly provided by Dr. Christina Ochsen-
bauer) were produced by transfection of the proviral 
plasmid into 293FT cells with PEI:DNA ratio of 4:1, for 
4  h. After 48  h, supernatant was removed and trans-
fected 293FT cells were co-cultured with C8166-R5 T 
cells. After a further 4  days, C8166-R5 cells were cen-
trifuged at 300×g and co-cultured with uninfected 
C8166-R5 cells for 72  h. Virus was then harvested as 
described above.
Microvesicle depleted HIV-1 virion stocks were puri-
fied as previously described [39, 58] with some modi-
fications. Briefly, viral stocks were concentrated over a 
17–25 % sucrose in PBS cushion in a Beckman SW55Ti 
rotor. Virions were resuspended in PBS, supplemented 
with 1  mM EDTA and 0.1  % BSA (binding buffer) with 
CD45 labeled magnetic beads (Miltenyi Biotec, Ger-
many) at 4  °C with gentle mixing for at least 4  h. Anti-
body conjugated beads were used at a concentration of 
1 μl of beads per 50 ng of p24 in the viral stock. Deple-
tion of CD45+ve microvesicles was performed over LD 
columns. Microvesicle depleted viral preparations were 
collected as the flow through from the column and re-
concentrated over 25  % sucrose cushions in a Beckman 
SW55Ti rotor and resuspended in PBS.
Immuno‑bead viral capture assay (IB‑VCA)
Purified virions, used at a concentration of 500 ng ml−1 
p24, were combined with the antibody of interest at a 
concentration of 10 μg ml−1 and brought to a final vol-
ume of 75  μl binding buffer then incubated at 37  °C 
for 1  h. 25  μl of protein G conjugated magnetic beads 
(Miltenyi Biotec) were then added to the antibody coated 
virions and incubated at 4  °C for 30  min. Separation of 
labeled fraction was performed on magnetic μ-columns. 
Fresh columns were primed with 1 ml binding buffer, and 
then the viral preparation was applied. Three washes of 
100  μl of binding buffer removed all unlabeled virions. 
The eluted portion was collected as the negative frac-
tion. The column was then removed from the magnet and 
washed four times with binding buffer. This portion of 
eluent was collected as the positive fraction. Virions were 
then lysed with Triton-X100 at a 1 % concentration with 
freezing. Each separation was performed in triplicate 
and at least three experiments were performed for each 
condition.
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The percentage of binding was determined by ELISA 
where the amount of either p24 or oligomeric Env pre-
sent in the positive fraction was expressed proportion-
ally to the total of the positive and negative fractions. 
ELISA for Env content of BaL was performed by coat-
ing 96-well plates with 5 μg ml−1 of galanthus nivalis 
lectin (GNA) (Sigma-Aldrich), followed by the lysed 
virion preparations [59]. Detection was done with 
5F3 monoclonal followed by HRP conjugated mouse 
anti-human IgG. Colorimetric signal was produced 
using the TMB substrate (Pierce) and absorbance read 
at 450  nm using a microplate reader (BMG Labtech). 
The 5F3 monoclonal recognizes a linear gp41 epitope 
adjacent to the N-terminal fusion peptide, and prefer-
entially binds trimeric and dimeric forms of Env [60], 
as GNA does not bind free gp41, this ELISA effec-
tively detects oligomeric forms of Env. A more sensi-
tive ELISA was used for quantification of CH162.c 
Env. 96-well plates were coated with sheep polyclonal 
capture antibody D7324 (Aalto Bio Reagents). Sorted 
viral preparations were then immobilized and detected 
with VRC01 followed by a secondary amplification 
with biotinylated goat anti-human IgG followed by 
Streptavidin-Poly-HRP40 and developed with TMB. 
The ELISA for p24-gag was performed using prepared 
quantification kits from the AIDS Vaccine Program, 
SAIC, Frederick, MD carried out according to the 
manufacturer’s instructions.
Immuno‑bead infectivity depletion assay
Untreated viral stocks were titrated on TZM-bl cells 
and luciferase production was measured as described 
[38] to determine the 50 % tissue culture infectious dose 
(TCID50). 103 TCID50 virions were incubated with the 
depletion antibody (10 μg) for 1 h at 37 °C, followed by 
addition of 50 μl protein G beads and 30 min incubation 
at 4 °C then depletion over μ-columns. Depleted virions 
were applied to TZM-bl cells in a twofold dilution series 
and luciferase production was measured after 24 h. Per-
centage depletion of infectivity was determined as the 
percent change in the area under the infectivity curve 
relative to the IgG isotype control depleted preparation. 
Control experiments were performed to demonstrate 
that no antibody was present in the eluted fraction.
Native and SDS‑PAGE and western blot
Native PAGE was performed as described previously 
with minor modifications [13, 48]. Briefly, inactivated 
virus was lysed for 10  min on ice with an equal vol-
ume of 2× lysis buffer (0.15 % Triton-X 100 in 1 mM 
EDTA and 1.5  M aminocaproic acid) and protease 
inhibitor cocktail (Roche Diagnostics, UK). Prior to 
loading on a 4–12  % Tris NuPAGE gel (Invitrogen) 
2× sample buffer composed of 100  mM MOPS, 
100  mM Tris–HCl pH 7.7, 40  % glycerol and 0.1  % 
Coomassie blue was added. Samples were separated 
on ice for 3  h at 100  V with cathode buffer contain-
ing 50 mM MOPS/50 mM Tris base pH 7.7 + 0.002 % 
Coomassie blue and same buffer without Coomas-
sie as anode buffer. Proteins were transferred onto a 
PVDF membrane under wet conditions using transfer 
buffer containing 10  % methanol for 2  h at 20  V on 
ice. Excess Coomassie blue was removed by washing 
3× with 100 % methanol for 10 min. Membranes were 
blocked in blocking buffer (4  % nonfat milk in PBS) 
for 1 h at RT and probed over night at 4 °C with cock-
tails of mAbs to gp120 (b12, 2G12, b6) or gp41 (2F5, 
4B3, 3D6) diluted in blocking buffer. Membranes were 
washed 4× for 10 min with wash buffer (PBS + 0.05 % 
Tween) and incubated for 1  h at RT with goat anti-
human Fc alkaline phosphatase conjugated second-
ary antibody (Sigma, UK) diluted 1:2000 in blocking 
buffer. The membranes were washed and developed 
with Sigmafast BCIP/NBT (Sigma, UK) for 5–10 min 
at RT. Band intensities were quantified using FIJI/
ImageJ v1.48  g gel analysis tools. Samples were pre-
pared for SDS PAGE analysis by concentration of anti-
body depleted virus fractions using 100,000MWCO 
vivaspin 500 microcolumns. Total protein concen-
tration was measured by absorbance at 280  nm on a 
Nanodrop Spectrophotometer. 25 μg total protein was 
loaded for each sample.
Concentrated virus samples are incubated in NuPAGE 
Reducing Agent and Tris–Glycine Sample Buffer (2×), 
at 95  °C, for 2  min, prior to loading on 4–12  % Tris–
Glycine gels (Novex). Protein samples were separated 
at room temperature using Tris–Glycine SDS running 
buffer (Novex) at 150 V for 90 min, transferred to PVDF 
membrane using semi-dry transfer in 39  mM glycine, 
48 mM Tris, with 20 % methanol. For detection of gp120 
HIV Env species, membranes were blocked in 3 % BSA in 
TBS and 0.1 % Tween for 1 h at room temperature with 
constant agitation. Env proteins were detected with b13 
hybridoma supernatant (a kind gift from Prof. George 
Lewis) overnight at 4  °C, followed by anti-mouse biotin 
at 1:5000 dilution (Southern Biotech) and streptavidin 
conjugated to Alkaline-phosphatase at 1:1000 dilution 
(MabTech), each for 1 h at room temperature with con-
stant agitation. Membranes were then developed with 
BCIP/NBT (Sigma, UK) for 30 min at room temperature. 
gp41 proteins were detected by blocking membranes 
with 1 % BSA in TBS and 0.1 % Tween and detected with 
a cocktail of 2F5, 4E10 and 5F3 (1 μg ml−1), followed by 
anti-human biotin at 1:1000 dilution (MabTech), Strepta-
vidin conjugated to Alkaline-phosphatase and BCIP/
NBT as described above.
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Visualization of virion depletion by nanoparticle tracking
The number of virus particles present in control (IgG) 
and antibody depleted virus samples was determined by 
nanoparticle tracking analysis using a Nanosight LM10 
instrument as previously described [34]. Samples were 
diluted to obtain particles counts between 2 ×  108 and 
9  ×  108 particles/ml to ensure accurate counting. For 
each sample, particle images were captured for 60  s in 
triplicate. Particle counts were assessed using screen gain 
of 10, and detection threshold of 4.0.
Viral neutralization assay
Depleted HIV-1BaL virions were prepared as for the infec-
tivity depletion assay with either 4B3 or 3D6. Serial dilu-
tions of antibody were pre-incubated with untreated 
or depleted virions at a range from 20  μg  ml−1 to 
156 ng ml−1 of nAbs of interest for 1 h at 37  °C. Virus-
antibody preparations were then applied to TZM-bl cells 
and incubated for 24  h at 37  °C after which cells were 
lysed and the Luciferase activity was measured as relative 
light units by a luminometer. 50 % inhibitory dose (IC50) 
was determined as the concentration of antibody which 
luminescence was reduced by 50  % compared to virus 
control wells.
Statistical analysis
Statistical comparisons were made using GraphPad Prism 
v6.00. Wilcoxon signed rank test was used to determine 
significance of differences in viral capture assays. All cor-
relations were determined by two-tailed Spearman corre-
lation analysis. 1-way ANOVA was used to determine the 
significance of effects of harvest time on viral capture and 
the variance in IC50 in neutralization assays after anti-
body depletion.
Additional files
Additional file 1: Figure S1. Depletion of infectious particles with a 
panel of Env-specific mAbs. Infectious stock of HIV-1BaL was treated with 
the specified antibody, and infectivity depleted as described in Figure 6 
legend. Data represent the mean of triplicate experiments.
Additional file 2: Figure S2. Depletion of infectious particles from pri-
mary HIV-1 isolates. (A) Depletion of HIV-1 strain Bx08 infectious particles 
with a panel of Env-specific mAbs. Infectivity depletion was performed as 
described in Figure 6 legend. Data represent the mean of duplicate exper-
iments. HIV-1 strain CH162.c was analyzed for correlation between (B)  % 
of p24 capture and  % infectivity depletion, (C)  % of p24 and  % of gp120 
capture, and (D)  % gp120 capture and  % infectivity depletion. Spearman 
correlation coefficients and associated p values are shown. Error bars 
indicate the standard deviation of 3 or 4 independent experiments.
Additional file 3: Figure S3. Monoclonal antibodies are completely 
retained by the magnetic column. Monoclonal antibody b12 was incu-
bated with Protein G magnetic beads in the absence of virus, and passed 
through a magnetic column. The resulting flow-through was added to 
HIV-1BaL and titrated on TZM-bl cells to determine if any residual inhibi-
tory activity had passed through the column. Luciferase production was 
measured after 24 h as a function of viral input.
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